{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:35:31Z","timestamp":1707525331988},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,25]]},"DOI":"10.7759\/cureus.45917","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T13:42:59Z","timestamp":1695649379000},"source":"Crossref","is-referenced-by-count":0,"title":["Transforming Acute Myeloid Leukemia Treatment Through Next-Generation Sequencing: A Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Vishal","family":"Devarkonda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Akabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner H","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017, 129:424-47. 10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone RM","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al.. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017, 377:454-64. 10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA- 0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne S","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, et al.. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA- 0701): a randomised, open-label, phase 3 study. Lancet. 2012, 379:1508-16. 10.1016\/s0140-6736(12)60485-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet JE","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, et al.. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018, 36:2684-92. 10.1200\/JCO.2017.77.6112","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd A","year":"2020","unstructured":"Burd A, Levine RL, Ruppert AS, et al.. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020, 26:1852-8. 10.1038\/s41591-020-1089-8","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003806","article-title":"Impact of treatment delay in acute myeloid leukemia revisited","volume":"5","author":"Juliusson G","year":"2021","unstructured":"Juliusson G, Hagberg O, Lazarevic VL, Lehmann S, H\u00f6glund M. Impact of treatment delay in acute myeloid leukemia revisited. Blood Adv. 2021, 5:787-90. 10.1182\/bloodadvances.2020003806","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33524","article-title":"Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia","volume":"127","author":"Amonoo HL","year":"2021","unstructured":"Amonoo HL, LeBlanc TW, Kavanaugh AR, et al.. Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. Cancer. 2021, 127:2500-6. 10.1002\/cncr.33524","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-454553","article-title":"Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia","volume":"121","author":"Bertoli S","year":"2013","unstructured":"Bertoli S, B\u00e9rard E, Huguet F, et al.. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013, 121:2618-26. 10.1182\/blood-2012-09-454553","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123717","article-title":"Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukemia","volume":"134(Supplement_1)","author":"R\u00f6llig C","year":"2019","unstructured":"R\u00f6llig C, Kramer M, Schliemann C, et al.. Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukemia. Blood. 2019, 134(Supplement_1):13. 10.1182\/blood-2019-123717","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184042-transforming-acute-myeloid-leukemia-treatment-through-next-generation-sequencing-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:29Z","timestamp":1707509189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184042-transforming-acute-myeloid-leukemia-treatment-through-next-generation-sequencing-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.45917","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,25]]}}}